Synergistic Augmentation of Beta-Lactams: Exploring Quinoline-Derived Amphipathic Small Molecules as Antimicrobial Potentiators against Methicillin-Resistant Staphylococcus aureus
ACS Infectious Diseases · 12.04.2024 · 10 (4) · 1267-1285
DOI: 10.1021/acsinfecdis.3c00696 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 05.03.2024. Verfasst von Surojit Ghosh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Smart Healthcare Department, Interdisciplinary Research Platform, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Infective Agents, Quinolines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Science and Engineering Research Board, Indian Institute of Technology Jodhpur, Ministry of Education, India.
Abstract (Originalsprache)
The escalation of bacterial resistance against existing therapeutic antimicrobials has reached a critical peak, leading to the rapid emergence of multidrug-resistant strains. Stringent pathways in novel drug discovery hinder our progress in this survival race. A promising approach to combat emerging antibiotic resistance involves enhancing conventional ineffective antimicrobials using low-toxicity small molecule adjuvants. Recent research interest lies in weak membrane-perturbing agents with unique cyclic hydrophobic components, addressing a significant gap in antimicrobial drug exploration. Our study demonstrates that quinoline-based amphipathic small molecules, SG-B-52 and SG-B-22, significantly reduce MICs of selected beta-lactam antibiotics (ampicillin and amoxicillin) against lethal methicillin-resistant Staphylococcus aureus (MRSA). Mechanistically, membrane perturbation, depolarization, and ROS generation drive cellular lysis and death. These molecules display minimal in vitro and in vivo toxicity, showcased through hemolysis assays, cell cytotoxicity analysis, and studies on albino Wistar rats. SG-B-52 exhibits impressive biofilm-clearing abilities against MRSA biofilms, proposing a strategy to enhance beta-lactam antibiosis and encouraging the development of potent antimicrobial potentiators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Smart Healthcare Department, Interdisciplinary Research Platform, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
- iHUB Drishti Foundation, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
- Department of Bioscience and Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan 342030, India.
- Centre for Research and Development of Scientific Instruments (CRDSI), Indian Institute of Technology, Jodhpur, Rajasthan, 342030, India.
ORCID-Profile: Surajit Ghosh
Förderung
- Science and Engineering Research Board
- Indian Institute of Technology Jodhpur
- Ministry of Education, India
Zitieren
APA
Ghosh, S., Sen, S., Jash, M., Ghosh, S., Jana, A., Roy, R., Mukherjee, N., Mukherjee, D., Sarkar, J., & Ghosh, S. (2024). Synergistic Augmentation of Beta-Lactams: Exploring Quinoline-Derived Amphipathic Small Molecules as Antimicrobial Potentiators against Methicillin-Resistant Staphylococcus aureus. ACS Infectious Diseases, 10(4), 1267-1285. https://doi.org/10.1021/acsinfecdis.3c00696
Vancouver
Ghosh S, Sen S, Jash M, Ghosh S, Jana A, Roy R, et al. Synergistic Augmentation of Beta-Lactams: Exploring Quinoline-Derived Amphipathic Small Molecules as Antimicrobial Potentiators against Methicillin-Resistant Staphylococcus aureus. ACS Infectious Diseases. 2024;10(4):1267-1285. doi:10.1021/acsinfecdis.3c00696
BibTeX
@article{Ghosh2024,
author = {Ghosh, Surojit and Sen, Samya and Jash, Moumita and Ghosh, Satyajit and Jana, Aniket and Roy, Rajsekhar and Mukherjee, Nabanita and Mukherjee, Dipro and Sarkar, Jayita and Ghosh, Surajit},
title = {Synergistic Augmentation of Beta-Lactams: Exploring Quinoline-Derived Amphipathic Small Molecules as Antimicrobial Potentiators against Methicillin-Resistant Staphylococcus aureus},
journal = {ACS Infectious Diseases},
year = {2024},
volume = {10},
number = {4},
pages = {1267--1285},
doi = {10.1021/acsinfecdis.3c00696}
}
EUVIMED